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Abstract
Aims/hypothesis A strategy to enhance pancreatic islet
functional beta cell mass (BCM) while restraining inflamma-
tion, through the manipulation of molecular and cellular
targets, would provide a means to counteract the deteriorating
glycaemic control associated with diabetes mellitus. The aims
of the current study were to investigate the therapeutic
potential of such a target, the islet-enriched and diabetes-
linked transcription factor paired box 4 (PAX4), to restrain
experimental autoimmune diabetes (EAD) in the RIP-B7.1
mouse model background and to characterise putative cellular
mechanisms associated with preserved BCM.
Methods Two groups of RIP-B7.1 mice were genetically
engineered to: (1) conditionally express either PAX4
(BPTL) or its diabetes-linked mutant variant R129W
(mutBPTL) using doxycycline (DOX); and (2) constitutively
express luciferase in beta cells through the use of RIP. Mice
were treated or not with DOX, and EAD was induced by
immunisation with a murine preproinsulin II cDNA expres-
sion plasmid. The development of hyperglycaemia was
monitored for up to 4 weeks following immunisation and
alterations in the BCM were assessed weekly by non-
invasive in vivo bioluminescence intensity (BLI). In parallel,
BCM, islet cell proliferation and apoptosis were evaluated
by immunocytochemistry. Alterations in PAX4- and
PAX4R129W-mediated islet gene expression were investi-
gated by microarray profiling. PAX4 preservation of endo-
plasmic reticulum (ER) homeostasis was assessed using
thapsigargin, electron microscopy and intracellular calcium
measurements.
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Results PAX4 overexpression blunted EAD, whereas the
diabetes-linked mutant variant PAX4R129W did not convey
protection. PAX4-expressing islets exhibited reduced insulitis
and decreased beta cell apoptosis, correlating with diminished
DNA damage and increased islet cell proliferation. Microar-
ray profiling revealed that PAX4 but not PAX4R129W
targeted expression of genes implicated in cell cycle and ER
homeostasis. Consistent with the latter, islets overexpressing
PAX4 were protected against thapsigargin-mediated
ER-stress-related apoptosis. Luminal swelling associated with
ER stress induced by thapsigargin was rescued in PAX4-
overexpressing beta cells, correlating with preserved cytosolic
calcium oscillations in response to glucose. In contrast, RNA
interference mediated repression of PAX4-sensitised MIN6
cells to thapsigargin cell death.
Conclusions/interpretation The coordinated regulation of
distinct cellular pathways particularly related to ER homeo-
stasis by PAX4 not achieved by the mutant variant
PAX4R129W alleviates beta cell degeneration and protects
against diabetes mellitus. The raw data for the RNA microar-
ray described herein are accessible in the Gene Expression
Omnibus database under accession number GSE62846.
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RIP-B7.1 . Type 1 diabetes
Abbreviations
BCL-2 B cell CLL/lymphoma 2
BCM Beta cell mass
BLI Bioluminescence intensity
BPTL RIP-B7.1/Pax4/rtTA/MIP-Luc
CABIMER Andalusian Center for Molecular Biology and
Regenerative Medicine
CALR Calreticulin
DOX Doxycycline
DsRed Discosoma sp. red fluorescent protein
EAD Experimental autoimmune diabetes
EM Electron microscopy
ER Endoplasmic reticulum
ERAD ER-associated protein degradation
GSIS Glucose-stimulated insulin secretion
KEGG Kyoto Encyclopaedia of Genes and Genomes
Luc Luciferase
MIP Mouse insulin promoter
PAX4 Paired box 4
RER Rough ER
RIP Rat insulin II promoter
rtTA Reverse tetracycline-controlled transactivator
si Small interfering
STZ Streptozotocin
Th1 T helper 1
UPR Unfolded protein response
Introduction
The islet of Langerhans is the core unit of the endocrine
pancreas, which regulates blood glucose homeostasis. Regu-
lation is achieved by the release of insulin from beta cells in
response to increasing levels of glucose and by the secretion
of glucagon from alpha cells under fasting conditions. Imbal-
ance in this circuitry leads to either hyperglycaemia, the hall-
mark of diabetes mellitus, or hypoglycaemia. Loss of beta cell
function coupled to insulin resistance of target tissues, which
usually associates with obesity and chronic low-grade inflam-
mation, defines type 2 diabetes [1]; high-grade T lymphocyte
inflammation mediating autoimmune beta cell destruction is
characteristic of type 1 diabetes [2].
Emerging evidence suggests that alterations in endoplas-
mic reticulum (ER) function contribute to beta cell disarray
in both type 1 and 2 diabetes [3]. In an attempt to restore ER
function and prevent apoptosis, cells activate the unfolded
protein response (UPR) [4]. The crucial role of the UPR in
balancing beta cell death and survival is illustrated in the
human Wolfram and Wolcott–Rallison syndromes, in
which mutations in UPR genes result in unresolved ER
stress, beta cell death and early-onset diabetes [5, 6]. Inter-
estingly, MODY genes such as Pdx1 and Hnf1a regulate
UPR-associated genes [7, 8]. These clinical conditions
suggest that islet-enriched transcription factors involved
in insulin biosynthesis and secretion also preserve the
BCM by limiting ER stress.
Paired box (Pax) genes encode transcription factors critical
for tissue development and cellular differentiation [9]. Paired
box 4 (PAX4) is necessary for the generation of pancreatic
islet cell progenitors and their differentiation towards beta
cells [10, 11]. Pax4 gene mutations have been associated with
type 1 and 2 diabetes as well as with ketosis-prone diabetes,
suggesting a key role of PAX4 in mature islets [12, 13].
Accordingly, overexpression of PAX4 in adult beta cells was
shown to block streptozotocin (STZ)-induced hyperglycaemia
in mice whereas the diabetes-linked variant PAX4R129Wwas
less efficient [14]. Despite differences in nitric oxide synthase
2 (NOS2) levels, both PAX4- and PAX4R129W-expressing
islets exhibited similar levels of cytokine-induced NO produc-
tion, indicating that the nuclear factor-κB (NF-κB) signalling
pathway was fully activated and that additional anti-apoptotic
pathways are involved in islet survival. Consistent with this
premise, PAX4 islets expressed higher levels of B cell CLL/
lymphoma 2 (BCL-2) [14]. Nonetheless, overexpression of
BCL-2 in islets did not prevent autoimmune-mediated beta
cell destruction and development of hyperglycaemia [15].
Thus, although these data highlight the protective function
of PAX4 against a chemical acute stress, whether such an
effect can also be conveyed in the context of a pathophysio-
logical autoimmune attack and the molecular mechanism
involved in this protection remain to be established.
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Herein, we investigated whether PAX4 and PAX4R129W
could promote beta cell health, preventing the development of
hyperglycaemia in the RIP-B7.1 mouse model of experimen-
tal autoimmune diabetes (EAD), and sought to characterise
the PAX4-regulated pathways implicated in islet survival
and expansion.
Methods
Animals and bioluminescence imagingMouse experiments
were approved by the local ethics committee and performed
according to the Spanish law on animal use RD 53/2013. The
rationale for using RIP-B7.1 (kindly supplied by B. O.
Boehm) rather than NOD mice for the current study is
provided in the electronic supplementary material (ESM)
Methods. BPTL mice were derived as outlined in Fig. 1a, b
and maintained on a C57bl/6 background. This mouse
harbours four transgenes: (1) RIP-B7.1, a construct coding
for the Cd80 gene under control of the rat insulin promoter
(RIP); (2) the tetracycline response element (TRE)/
cytomegalo mosaic virus (CMV) Pax4, a tetracycline-
inducible CMV promoter driving Pax4 expression; (3) the
RIP-reverse tetracycline trans-activator (rtTA), a construct
allowing selective expression of Pax4 in beta cells exposed
to DOX; and (4) the MIP-Luciferase (Luc), a construct that
expresses luciferase under the mouse insulin promoter (MIP),
allowing assessment of BCM using non-invasive in vivo im-
aging technology. Induction of Pax4 or Pax4R129W gene
expression using doxycycline (DOX) was performed as pre-
viously described [14], while EAD was achieved by i.m.
immunisation of 9-week-old BPTL animals with 50 μg of
pC1/ppins plasmid DNA (1 μg/μl) encoding the murine
preproinsulin II. Blood glucose levels were measured using
a Precision Xceed glucometer (Abbott, Madrid, Spain).
Bioluminescence imaging was performed using a Xenogen
IVIS 50 imaging system as previously described [16].
Islet isolation and treatment Islets were isolated and cultured
as previously described [14]. Total RNAwas extracted using
the RNeasy Micro Kit (Qiagen, Madrid, Spain) and quantita-
tive (q)-PCR was performed as described previously [17].
Primer sequences can be obtained on request. For studies on
thapsigargin-induced ER stress and apoptosis, islets from ei-
ther Pax4/rtTA or Pax4R129W/rtTA transgenic mice were
treated with 1 μg/l DOX for 96 h or left untreated [14]. Fluo-
rescence of theDiscosoma sp. red fluorescent protein (DsRed)
correlating with Pax4 or Pax4R129W expression was moni-
tored using an ImageXpress Micro System (Molecular
Devices, Wokingham, UK). Islets were then treated or not
with 1 μmol/l thapsigargin for 48 h and apoptosis was
assessed by ELISA (Roche Diagnostics, Mannheim,
Germany). Glucose-stimulated insulin secretion (GSIS) was
performed as previously described [18].
Intracellular Ca2+ measurements Isolated islets were incu-
bated for 1 h at room temperature with 2 μmol/l Fura-2
(Qiagen). Fluorescence recordings were performed using an
inverted epifluorescence microscope (Axiovert 200; Zeiss,
Jena, Germany) equipped with 360 nm and 380 nm band-
pass filters. Recordings were expressed as the ratio of
fluorescence at 360 nm and 380 nm (F360/380). Images were
taken every 3 s. Intracellular [Ca2+] changes in response to
stimuli were analysed as previously described [19].
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Fig. 1 Characterisation of the BPTL mice. (a) Schematic diagram
showing the generation of the BPTL mouse. (b) Genotyping of BPTL
mice by PCR using primer sets for Cd80, Pax4, Luc and rtTA. (c) The
bioluminescent signal was correlated with age in BPTL male (white
diamonds, n = 5) and female (black rectangles, n = 5) mice. (d) BCM
calculated as a percentage of total islet cells and compared with
8-week-old animals was assessed in both sexes. On average, cells from
at least 25 islets were counted per animal, with each group comprising at
least 5–6 mice. (e) Blood glucose levels were measured for up to 35 days
in BPTL mice (n = 3) immunised (black circles) or not (control, white
squares). (f) Pancreatic sections of BPTL mice at the indicated time after
immunisation were co-immunostained for glucagon (green) and insulin
(red). Nuclei were stained with DAPI (blue). Scale bar, 25 μm. GCG,
glucagon; INS, insulin
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MIN6 cell culture and RNA interference MIN6 cells were
cultured as previously described [20] and transfected with
either 50 μmol Pax4 small interfering (si)RNA (Sigma) or
scramble siRNA using Oligofectamine (Life Technologies,
Madrid, Spain). Cells were either processed for RNA or
treated with thapsigargin (Sigma-Aldrich, Madrid, Spain) to
assess apoptosis 48 h after transfection.
Immunohistochemistry and electronmicroscopyDissected
pancreases were fixed in 4% paraformaldehyde and processed
at the Histology Core Facility, Andalusian Center for
Molecular Biology and Regenerative Medicine (CABIMER).
A detailed immunocytochemistry protocol along with the list
of antibodies used is provided in ESM Methods and ESM
Table 1. Validation of antibodies was performed on appropri-
ate control samples. The BCM and islet cell number were
assessed as described elsewhere [21]. Apoptosis, proliferation
and DNA damage were quantified by counting caspase-3-,
Ki67- and p53BP1-positive cells, respectively, in at least 20
to 50 islets from three independent pancreatic sections from
3–4 mice per group. Insulitis scoring was performed as
previously outlined [22]. For electron microscopy (EM), pan-
creatic islets were processed using a standard Spurr protocol
[23]. Images were acquired with an electron-multiplying
charge-coupled device (EMCCD) camera (TRS 2 k×2 k).
RNA microarray Labelled cRNA samples were prepared
from pools of at least 100 islets isolated from either Pax4/
rtTA or Pax4R121W/rtTA transgenic animals (8-week-old
females) treated with DOX or not treated [14]. Three prepara-
tions of cRNA per group were then hybridised to the
GeneChip Mouse Gene 1.0 STArray chip (Affymetrix, Santa
Clara, CA, USA) using the standard protocols of the Genomic
Core Facility, CABIMER. Raw data are accessible in the
Gene Expression Omnibus database under accession number
GSE62846, while its analysis is described in ESM Methods.
Statistical analysis Results are expressed as mean ± SEM.
Statistical differences between two conditions were estimated
using the unpaired Student’s t test. One-way ANOVA was
used for comparison of more than two groups with Bonferroni
post hoc test or non-parametric Mann–Whitney test (*p<0.05
and **p<0.01).
Results
PAX4 expression blunts EAD in immunised BPTL mice
We first monitored in vivo the bioluminescence intensity
(BLI) emitted by beta cells of BPTL mice from 4 to 65 weeks
of age (Fig. 1c). In 4-week-old mice, the bioluminescence
signal was two fold higher in male mice than females.
Consistent with a transient wave of beta cell apoptosis and
decreased rate of islet growth around weaning [24], both sexes
displayed a decline in BLI signal between the fourth and the
ninth week (Fig. 1c). Thereafter, this signal did not significant-
ly change with age (Fig. 1c). Morphometric evaluation
revealed that the volume density of beta cells was similar in
animals aged from 4 to 16 weeks (Fig. 1d). Thus, by 9 weeks
of age the bioluminescent signal reflects the mass and function
of beta cells, which we hereafter refer to as the functional beta
cell mass (BCM). Similar to the RIP-B7.1 animal, immunised
BPTL mice developed hyperglycaemia within 21 days
(Fig. 1e) due to a gradual loss of beta cells (Fig. 1f), whereas
non-immunised mice remained normoglycaemic (Fig. 1e, f).
We next determined whether PAX4 expression could
prevent EAD. Five-week-old BPTL mice were treated with
DOX for 4 weeks prior to immunisation. Compared with
control mice, islets from treated mice revealed a ten fold
increase in Pax4 expression (Fig. 2a), but no change in
Cd80 transcript levels (Fig. 2b). DOX treatment did not alter
the BCM or GSIS of PAX4-expressing islets (Fig. 2c, d).
Nine-week-old untreated controls remained normoglycaemic
and featured no variation in bioluminescent signal for up to
28 days (Fig. 2e). Immunised BPTL mice without DOX
revealed a rapid decrease in BLI, reaching undetectable levels
by day 28 post-immunisation, which coincided with sustained
hyperglycaemia (Fig. 2f). Escalation in blood glucose level
observed 21 days after immunisation correlated with a 60%
decrease in BLI. DOX-treated and immunised BPTL mice
maintained both normoglycaemia and bioluminescent signal
(Fig. 2g). Protection was extended up to 63 days (Fig. 2h), at
which point 65% of immunised and DOX-treated BPTL mice
developed hyperglycaemia, probably because of the robust
immune attack conveyed by CD80 overexpression.
Immunised and DOX-treated RIP-B7.1 mice developed
hyperglycaemia (ESM Fig. 1), excluding a protective effect
mediated by the antibiotic through alteration in the gut
microbiome [25, 26]. Non-DOX-treated BPTL mice suffered
a 40% and 80% reduction in the functional BCM after 21 and
28 days of immunisation, respectively. Such changes were not
observed in DOX-treated mice (Fig. 3a, b). By day 63, the
latter animals retained approximately 50% of the functional
BCM (Fig. 3b).
PAX4 improves beta cell health and mitigates the autoim-
mune attack Insulitis assessment at 28 days after
immunisation revealed that 65% of islets of DOX-treated
BPTLmice were insulitis free (grade 0), whereas 90% of islets
derived from non-DOX-treated BPTL mice displayed severe
insulitis (grades 2–4) (Fig. 4a). Even at 63 days after
immunisation only 50% of islets from DOX-treated BPLT
mice displayed mild insulitis (Fig. 4a). DOX treatment also
diminished the percentage of cleaved CASPASE-3-positive
islet cells in immunised animals (Fig. 4b and ESM Fig. 2a).
DNA damage induced by NO and reactive oxygen species
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(ROS) contributes to beta cell death [27, 28]. Immunostaining
for the double-strand DNA break marker p53BP1 revealed
that PAX4 overexpression reduced DNA damage in islets
from either immunised BPTL or STZ-treated mice (Fig. 4c).
These changes were paralleled by increased cell proliferation
in DOX-treated BPLT islets (Fig. 4d and ESM Fig. 2b).
PAX4 regulates genes important for beta cell proliferation
and ER homeostasis Transcriptome profiling was conducted
on PAX4 and PAX4R129W islets to highlight PAX4 target
genes involved in beta cell health, and those altered by the
diabetes-linked mutant variant R129W. We initially demon-
strated that DOX-treated and immunised mutBPTL mice
developed hyperglycaemia (Fig. 5a) with an incidence of
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DOX group. On average, cells from at least 25 islets were counted per
animal (n = 4–6). (d) Insulin secretion by isolated BPTL islets treated or
not with DOX was assessed in 30 min static incubations in response to
glucose at 2.5 mmol/l (white bars) and 16.5 mmol/l (black bars). Insulin
released was quantified by ELISA and expressed as a percentage of total
cellular insulin content. n= 4–7, *p< 0.05. BLI (white diamonds) and
blood glucose levels (black circles) was measured weekly for up to
4 weeks in (e) control untreated BPTL mice (n = 4), (f) immunised
non-DOX-treated (n= 6) and (g) immunised DOX-treated BPTL animals
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approximately 75% by day 28 compared with 100% in non-
DOX-treated immunised animals (Fig. 5b). Transcriptome
analysis revealed that 770 transcripts were upregulated and
449 were downregulated in PAX4 islets, whereas 1437 genes
were upregulated and 1136 downregulated in PAX4R129W
islets. Genes showing the largest changes are listed in ESM
Table 2. Notwithstanding this list, we substantiated by qPCR
our previous findings [14] that Mafa transcript levels were
repressed whereasNos2 levels were unchanged in PAX4 islets
(ESM Fig. 3). However, Bcl2 levels were not increased in
PAX4-overexpressing islets (ESM Fig. 3), arguing against a
role of this factor in protecting from EAD [15].
A functional enrichment analysis disclosed that the cell
cycle and the protein processing in ER pathways were
among the top upregulated Kyoto Encyclopaedia of Genes
and Genomes (KEGG) pathways in islets overexpressing
PAX4, but were among the most significantly downregu-
lated pathways in islets overexpressing PAX4R129W
(adjusted p values < 0.05) (Fig. 5c, d and ESM Tables 3
and 4). To contrast the expression levels of genes contrib-
uting to these pathways, we generated heat maps amenable
to statistical analysis (raw p value < 0.05). Several genes
associated with cell cycle were increased in PAX4 islets,
while remaining unchanged or having lower levels in islets
expressing PAX4R129W (Fig. 5e). Genes encoding
proteins for peptide folding (Hspa5 [also known as Bip],
Calr), ER–Golgi translocation (Lman1, Lman2, Sec23b
and Plaa) and ER-associated protein degradation (ERAD)
(Ufd1l, Derl3, Pdia4, Ssr3, Syvn1 and Dnaja2/Hsp40)
were upregulated after overexpression of PAX4, but were
downregulated after overexpression of PAX4R129W
(Fig. 5f). The UPR-associated genes Mbtps2, Eif2ak3 and
Mapk10 were upregulated in PAX4 islets and were
marginally altered in PAX4R129W islets (Fig. 5f).
PAX4 targets ER integrity and calcium homeostasis,
protecting cells against apoptosis Given that PAX4 but
not PAX4R129W targets genes that are involved in ER
homeostasis, we investigated the contribution of ER to
PAX4-mediated beta cell health. We initially assessed
expression levels of calreticulin (Calr), a major Ca2+
binding protein of the ER lumen and of galectin-9
(Lgals9), a protein involved in immune modulation.
Although Pax4 and Pax4R129W transcript levels were
increased three fold, Calr and Lgals9 expression levels
were only increased in PAX4 islets (Fig. 6a, b). As Ca2+
handling by the ER affects the cell sensitivity to apoptosis,
we assessed whether PAX4 and PAX4R129W could
protect against ER-stress-induced beta cell apoptosis. Islets
treated in vitro with DOX exhibited DsRed fluorescence,
confirming the expression of the transgenes (Fig. 6c).
Thapsigargin exposure prompted a two fold increase in
apoptosis in control mice (Fig. 6d). DOX reduced both
basal and thapsigargin-induced apoptosis only in PAX4
islets (Fig. 6d). However, Pax4 siRNA-mediated
repression in MIN6 cells caused a 60% decrease in Calr
transcript levels, with a concomitant sensitisation to
thapsigargin-induced apoptosis compared with siControl
and thapsigargin-treated cells (Fig. 6e, f).
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(−) DOX group; †p< 0.05 vs immunised day 28 and (−) DOX group.
(b) Apoptosis was assessed by immunohistochemical analysis of cleaved
caspase-3 in pancreatic islets from BPTLmice treated (black ovals) or not
(white ovals) with DOX and killed at the time points. As similar results
were obtained for days 28 and 35, the data were combined as a single time
point. n= 5–6, *p < 0.05, (+) vs (−) DOX groups within each time point.
(c) The average number of 53BP1 foci per beta cell was assessed from
pancreatic islets of either 14-day-old immunised BPTLmice or 2-day-old
STZ-treated PAX4 mice exposed (+) or not (−) to DOX. n = 5–6,
*p< 0.05 vs untreated mice; †p< 0.05 vs DOX-untreated immunised or
STZ-treated mice. (d) Cell proliferation was assessed by the combined
immunohistochemical analysis of Ki67 in pancreatic islets from BPTL
mice treated (black ovals) or not (white ovals) with DOX and killed at the
time points. n = 5–6, *p < 0.05, (+) vs (−) DOX groups within the time
point. IMM, immunised
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Perturbation in beta cell ER homeostasis has been linked to
ER dilation [29, 30]. Accordingly, islets from non-DOX-
treated Pax4 transgenic mice exposed in vitro to thapsigargin
displayed distension and fragmentation of the rough ER
(RER) in beta cells, an effect prevented by PAX4 overexpres-
sion (Fig. 7). ER calcium release in response to carbachol was
then measured. Calcium release in PAX4-overexpressing beta
cells from isolated islets was marginally higher than that of
controls cells (Fig. 8a–d). As the higher ER-Ca2+-buffering
capacity induced by PAX4 could mask the carbachol-
stimulated calcium release, we measured cytosolic Ca2+
signals in response to glucose. Glucose-induced calcium
oscillations were improved in isolated islets overexpressing
PAX4 compared with control islets (Fig. 8e, f). The overall
Ca2+ signal was also higher in PAX4-overexpressing cells
(Fig. 8g–i). Thus, PAX4 overexpression leads to improve
ER and Ca2+ homeostasis in the face of beta cell stress as
encountered during the islet isolation procedure or an immune
attack.
Discussion
Inflammation is a common denominator in types 1 and 2
diabetes, and leads to beta cell failure and death, predominant-
ly by apoptosis. As yet, there is no ‘unifying hypothesis’ for
the mechanisms triggering beta cell deterioration [31, 32];
deciphering the molecular roadmap regulated by factors such
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as PAX4—mutations in which are linked to both forms of
diabetes—may help identify common pathways. Herein, we
provide proof-of-concept that PAX4, but not PAX4R129W,
preserves the BCM and delays the development of
hyperglycaemia in the RIP-B7.1 mouse model of EAD. This
highlights the mechanistic differences between the wild type
and mutant variant.
Consistent with previous reports exploiting the RIP-
B7.1 model, 90–100% of immunised non-DOX-treated
RIP-B7.1 mice bearing either the Pax4 or Pax4R129W
transgene developed hyperglycaemia within 3 weeks,
correlating with insulitis and beta cell destruction [33].
DOX-med i a t e d i ndu c t i o n o f Pax4 p r e v e n t e d
hyperglycaemia development in BPTL animals up to
4 weeks after immunisation, whereas Pax4R129W induc-
tion partially reduced the hyperglycaemic incidence in
mutBPTL mice. Thus, PAX4 blunts hyperglycaemia in
an autoimmune context, in contrast to several other
factors such as caspase-3-generated RAS p21 protein
activator 1 (RasGAP) N-terminal fragment (fragment N),
cytokine response modifier A (CRMA) or BCL-2 which,
d e s p i t e i n c r e a s i n g BCM, c o u l d no t p r e v e n t
hyperglycaemia in animal models of type 1 diabetes
[15, 22, 34]. Our data imply that in addition to inhibiting
apoptosis, PAX4 is involved in additional regulatory path-
ways, possibly including immune modulation. Corre-
spondingly, insulitis was reduced after PAX4 overexpres-
sion, an effect not attributable to a non-specific repression
of the Cd80 transgene that facilitates the immune
response. Our observations extend the analogous findings
that inhibition of vascular endothelial growth factor recep-
tor 2 (VEGFR-2) in NOD mice reversed hyperglycaemia
by abrogating insulitis and restoring islet cell function
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PAX4, galectin-9 (Lgals9) and calreticulin (Calr) transcript levels were
assessed in (a) PAX4 or (b) PAX4R129W transgenic mice treated (black
bars) or not treated (white bars) with DOX for 1 month. The relative
mRNA levels were normalised to transcript levels of the housekeeping
gene β-actin. Data were calculated as fold change compared with the
values in control, non-DOX-treated animals. n = 3, **p < 0.01 and
*p< 0.05. (c) Pax4 or Pax4R129W induction in DOX-treated islets was
qualitatively assessed through DsRed fluorescence. Scale bar, 10 μm.
(d) Control (white bars), PAX4-expressing (black bars) and
PAX4R129W-expressing (grey bars) islets were then challenged with
1 μmol/l thapsigargin or not challenged and apoptosis was measured by
ELISA. Results expressed as per cent change compared with control
non-thapsigargin-treated islets. n = 5, *p < 0.05. (e) Pax4, Calr and
cyclophylin expression levels were measured in MIN6 cells treated with
siControl (white bars) and siPax4 (black bars). mRNA levels were nor-
malised to the transcript levels of the housekeeping gene β-actin. Data
were calculated as fold change compared with the values in siControl-
treated cells. n = 4, *p < 0.05. (f) Apoptosis was evaluated in control
MIN6 (white bars), and cells treated with siControl (grey bars) or siPax4
(black bars), untreated or treated with thapsigargin. Results are expressed
as fold change compared with control non-thapsigargin-treated cells.
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Fig. 7 ER integrity is preserved in PAX4-overexpressing islets. Two sets
(upper and lower) of beta cell micrographs from islets isolated from
PAX4 transgenic mice, treated with DOX or not treated, and challenged
with 1 μmol/l thapsigargin or not challenged. Arrows indicate the RER.
Inset is enlarged below each image. Scale bar, 0.5 μm. N, nucleus;
V, insulin vesicles
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[35]. Although the mechanism by which PAX4 acts at the
interface of beta cells and the immune system to blunt
insulitis and improve islet recovery remains undefined,
our genetic analysis revealed that Lgals9 was specifically
upregulated in PAX4 islets. This gene induces apoptosis
of differentiated T helper 1 (Th1) cells [36], and its over-
express ion in NOD mice reduced insul i t i s and
hyperglycaemia [37], prolonging the survival of grafts
[38]. It is therefore plausible that, by enhancing Lgals9
expression, PAX4 may downregulate Th1 function,
partially impeding insulitis and improving islet survival.
Transcriptome profiling revealed that cell-cycle-associated
genes upregulated by PAX4 were downregulated by
PAX4R129W, despite comparable expression levels of both
transgenes. Specifically, the type 2 diabetes-associated cyclin-
dependent kinase inhibitor 2A, which strongly inhibits the
proliferative cyclin-dependent kinase 4 (CDK4) [39], was
enriched in PAX4R129W islets whereas it was decreased in
PAX4 islets. Reciprocally, cyclin D3, which promotes beta
cell survival, was increased in PAX4- but not in
PAX4R129W-overexpressing islets [40]. These findings
provide some molecular insights into the pathogenic effect
of the R129W mutation on beta cell plasticity.
Our data also reveal that PAX4, but not PAX4R129W, is
a key regulator of ER function by a combined targeting of
genes involved in UPR, Ca2+ homeostasis, ER–Golgi
translocation, and ERAD. The functional importance of
the transcriptional changes in these genes was validated
by the capacity of PAX4 to prevent thapsigargin-induced
ER ultrastructural abnormalities and apoptosis of beta
cells, consistent with the finding that PAX4-binding sites
are enriched within the promoter region of palmitate-
modified ER stress response genes [41]. In contrast, re-
pression of PAX4-sensitised MIN6 cells to thapsigargin
cell death correlates with reduced CALR levels.
Calreticulin is a Ca2+ chaperone of the ER, which contrib-
utes to the quality control of protein folding [42]. Overex-
pression of CALR in MIN6 cells enhances ER Ca2+ stores
and prevents NO-induced apoptosis [43]. In this context,
the production of NO and ROS induced by inflammatory
cytokines in the diabetic environment promotes beta cell
death by a variety of mechanisms, including the induction
of irreversible double-strand DNA breaks [27, 44]. We
found that PAX4 blunts DNA damage in two models of
experimental diabetes, pointing to a general protective
mechanism, possibly through preserved ER homeostasis,
implicating CALR [43]. The finding that PAX4-
overexpressing islets exhibited improved glucose-induced
Ca2+ oscillations points to this premise. Loss of oscillatory
capacity is associated with diminished islet glucose sensi-
tivity and increased ER dysfunction [45]. Thus, amplified
Ca2+ content in the CALR-enriched ER of PAX4-
overexpressing beta cells may impact cytosolic calcium
dynamics [43, 46], thereby preventing activation of
downstream apoptotic pathways under stress conditions.
We conclude that PAX4 favours beta cell survival and
regeneration in various deleterious inflammatory and high-
grade inflammatory environments, such as autoimmunity,
through the coordinated regulation of immune modulation,
cell cycle, cell survival, ER homeostasis and DNA repair.
While both PAX4 and PAX4R129W modulate these
pathways, it is the wild-type transcription factor that conveys
pro-survival properties by increasing the expression of
selected adaptive genes.
Fig. 8 PAX4-overexpressing islets exhibit normal calcium oscillation in
response to glucose. Carbachol-stimulated (100 μmol/l) intracellular re-
lease of Ca2+ wasmeasured in intact islets (a) treated with DOXor (b) not
treated. As indicated by the bars, islets were exposed to Ca2+-deficient
medium containing 2 mmol/l EGTA prior to applying 100 μmol/l carba-
chol. (c) Analysis of the AUC for the time of the stimulus with carbachol
from experiments shown in (a) and (b). (d) Analysis of the Ca2+ peak
amplitude in response to carbachol challenge. (n = 5–6). Representative
Ca2+ signals in response to 11 mmol/l glucose measured in intact islets (e)
treated with DOX or (f) not treated. (g) Analysis of the AUC for the last
10 min of the glucose stimulus recording shown in (e) and (f). (h)
Analysis of the amplitude of the first Ca2+ transient in response to the
glucose challenge. (i) Analysis of the basal fluorescence during the first
minute of the experiments. n = 9; **p ≤ 0.01 and ***p ≤ 0.001. ΔF;
fluorescence increase
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